Skip to main content
Equibles
MPT logo

MPT · Medical Properties Trust Inc · Metrics

Track MPT — free

Use MPT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MPT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.74 -0.11 (-3.86%)
S&P 600 member Russell 1000 member Rebalance outlook locked
Market Cap
$1.70B
Shares
598.10M
Volume · Oct 20 14.99M Avg daily vol (3M) 9.93M

MPT metrics

88 of 126 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.74
Market cap
$1.70B

Price action

20 metrics
Price change (1W)
-9.2%
Price change (30D)
-21.9%
Price change (3M)
-40.0%
Price change (6M)
-45.8%
Price change (YTD)
-43.0%
Price change (1Y)
-44.6%
Trailing year
Price change (5Y)
-86.1%
52-week high
$6.02
52-week low
$2.85
Change from 52-week high
-52.7%
Change from 52-week low
+0.0%
Annualized volatility
37.7%
Annualized volatility (3M)
42.9%
Beta
0.5
RSI (14D)
21.1
Price vs SMA 50
-22.5%
Price vs SMA 200
-39.1%
Avg volume (3M)
9.76M
Relative volume
2.5
Average dollar volume
$36.38M

Company

3 metrics
Sector
Real Estate
Industry
REIT - Healthcare Facilities
Shares outstanding
598.10M

Valuation

14 metrics
P / FFO
9.2×
Company-stated · FY2025 · reciprocal yield 10.9%
P / AFFO
—
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
10.9×
reciprocal yield 9.2%
EV / EBITDA
10.6×
reciprocal yield 9.5%
EV / EBIT
13.4×
reciprocal yield 7.4%
P / sales
1.8×
reciprocal yield 56.6%
P / book
0.4
reciprocal yield 249.9%
FCF yield
—
TTM · current market cap
Buyback yield
1.6%
P / FCF
—
P / operating cash flow
7.9
reciprocal yield 12.6%
Earnings yield
-1.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
30.9×
reciprocal yield 3.2%
EV / revenue historical average (3Y)
13.4×
reciprocal yield 7.5%
EV / revenue historical average (5Y)
12.9×
reciprocal yield 7.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
12.6%
Trailing 12 months
Payout ratio
—
Shareholder yield
1.6%
Dividend / share (TTM)
$0.36
Dividend growth YoY
+12.5%
Dividend growth streak
0
Last ex-dividend
2026-09-10

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
90.7%
Operating margin
—
Trailing 12 months
Net margin
-3.0%
Gross profit (TTM)
$920.47M
Operating profit (TTM)
$485.58M
Net income (TTM)
−$30.44M
Trailing 12 months
Diluted EPS (TTM)
$-0.06
FCF margin
—
Effective tax rate
—

Per share

13 metrics
FFO per diluted share
$0.31
Company-stated · FY2025
AFFO per diluted share
—
Revenue per diluted share (TTM)
$1.70
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$1.38
EBITDA per diluted share (TTM)
$1.76
Net income per diluted share (TTM)
$-0.05
Operating cash flow per diluted share (TTM)
$0.38
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$7.54

Growth

11 metrics
Revenue growth YoY
+7.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.02B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-0.5%
Year over year · fewer shares
Revenue CAGR (3Y)
-14.3%
Revenue CAGR (5Y)
-4.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-0.7%
Return on assets
-0.2%
Debt / equity
2.2
Current ratio
—
EBITDA (TTM)
$617.56M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
7.7
Return on invested capital
—
Trailing 12 months
Net cash
−$9.31B
Latest balance sheet
Cash & equivalents
$396.56M
Total assets
$14.75B
Total debt
$9.70B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$226.82M
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$8.65M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
497
13F filer change QoQ
-7
Institutional ownership
64.2%
Conviction holders (share of 13F filers)
0.2%
Crowding (high-turnover and private-fund holders)
11.3%
Private-fund adviser ownership
10.8%
Active holders' share change QoQ
+6.3%
Holder tenure
14.0
Price vs estimated holder cost
-12.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
25.1%

Short interest

3 metrics
Short interest
24.4%
Latest settlement · 11.8 days to cover
Days to cover
11.8d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
$9,545
Insider-sentiment score
72 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1287865 CUSIP 58463J304 13F (30d) 64 filings 62 filers Visit website Investor relations